查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
循環腫瘤細胞 (Ctc) 市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190306

循環腫瘤細胞 (Ctc) 市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Circulating Tumor Cells (Ctc) Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

循環腫瘤細胞 (CTC) 市場預計在預測期內 (2022-2027) 的複合年增長率為 9.5%。

COVID-19 大流行影響了世界各地的醫療保健系統，擾亂了許多醫療機構的正常護理，並使易受傷害的癌症患者面臨巨大風險。 例如，“COVID-19 大流行對癌症治療的影響：一項全球合作研究”，2020 年 9 月，4 月 21 日至 5 月 8 日期間，共有來自 6 大洲 54 個國家/地區的 356 個中心參與。據報導， 這些設施每年為 716,979 名新癌症患者提供服務。 大多數 (88.2%) 報告在大流行期間面臨提供護理的挑戰。 作為先發製人戰略的一部分，55.34% 縮減了服務，但其他常見原因包括系統超載 (19.94%)、缺乏個人防護設備 (19.10%)、人員短缺 (17.98%)、藥物獲取限制 (9.83%)。 因此，這表明 COVID-19 在化療和放療服務減少以及正在進行的研發研究方面擾亂了癌症治療，從而影響了市場的增長。

此外，2021 年 9 月發表的一項研究“COVID-19 鎖定與新診斷轉移性結直腸癌患者的腫瘤負擔相關”通過循環腫瘤 DNA 確定了 COVID-19 鎖定的新診斷。他們評估了對癌症病例的影響，並報告說，鎖定後診斷出的患者的腫瘤負擔明顯高於鎖定前診斷出的患者。 這項研究表明，在 COVID-19 實施期間，腫瘤負擔顯著增加，對市場增長產生了巨大影響。

推動循環腫瘤細胞 (CTC) 市場增長的主要因素是生物醫學成像和生物工程技術的進步、對預防醫學和伴隨診斷的需求增加以及癌症患病率的增加。

隨著全球癌症負擔的增加，必鬚根據地區和國家優先事項調整癌症治療。 例如，根據世界衛生組織 (WHO) 於 2021 年 9 月發布的最新消息，到 2020 年，癌症將導致全球約 1000 萬人死亡。 2020年，最常見的癌症（按新發病率計算）是乳腺癌（226萬例）、肺癌（221萬例）、結直腸癌（193萬例）、前列腺癌（141萬例）、皮膚（非黑色素瘤）（120萬例）和胃（109 萬例）。

此外，根據 Globocan 2020 年的統計數據，2020 年有 19,292,789 人被診斷出患有癌症。 在上述同一份材料中，預計2040年癌症患者人數將達到3020萬。 癌症負擔的增加是由多種因素造成的，包括人口增長和老齡化，以及隨著社會和經濟發展，某些癌症病因的患病率發生變化。 例如，根據世界衛生組織 (WHO) 的數據，到 2021 年 9 月，大約三分之一的癌症死亡將與煙草使用、高體重指數、酒精使用以及水果和蔬菜攝入量低有關。，歸因於缺乏身體活動。 因此，預計增加煙草消費會導致癌症患病率增加，從而促進市場增長。

此外，近期臨床研究取得的良好結果也可能會在未來帶來顯著的市場增長。 例如，2021 年 2 月啟動了一項名為“熱休克蛋白 (HSP)70 以量化和表徵晚期或轉移性腫瘤患者的循環腫瘤細胞”的研究，以證明熱休克蛋白 HSP70 在晚期或轉移性腫瘤患者中循環據透露，它可以評估分離和量化腫瘤細胞 (CTC) 的能力。

因此，由於上述因素，研究涵蓋的市場預計在研究期間將顯著增長。 然而，與高診斷成本、缺乏認識和採用先進 CTC 技術的意願低相關的檢測和表徵 CTC 的技術困難預計將進一步阻礙市場增長。

主要市場趨勢

在循環腫瘤細胞（CTC）市場中，陰性富集部分有望佔據主要市場份額

對於陽性富集方法，CTCs 由於其異質性而無法分離。 然而，在負富集方法中，血細胞的精確消耗允許分離外來和完整的 CTC。 由於這種負濃縮技術的優越性，預計未來會被採用。

此外，預計在不久的將來，各種類型癌症患病率的上升也將推動這一細分市場的增長。 根據國際癌症研究機構2020年的統計，肝癌是全球第6大常見癌症和第3大癌症死因，新發病例905,677例，估計死亡人數為830,180人。 東亞的發病率最高，為 491,687 例。 此外，北美的發病率為 46,599 人，西歐為 26,128 人。 總體而言，男性肝癌的發病率大約是女性的三倍。

此外，根據美國癌症協會 2022 年 1 月發表的一篇論文，腎癌是美國男性和女性最常見的 10 種癌症之一。 總體而言，患腎癌的終生風險相當高，男性約為 46 分之一，女性約為 80 分之一。 隨著這種負擔的增加，癌症預防已成為最重要的問題之一。 循環腫瘤細胞的分析對於監測疾病進展和對治療的反應非常重要，特別是對於新型抗癌藥物的伴隨診斷和研究疾病進展的機制。

負富集在分離 CTC 方面也優於正富集，因此預計該部分在預測期內將呈現高增長。 例如，在 2021 年 10 月發表的一項題為“使用 3D 打印設備從未經處理的全血中負向富集循環腫瘤細胞”的研究中，負向富集方法導致了對 CTC 以及粘附免疫劑的無偏檢測。它是據說是有利的，因為它可以生成不含 的完整腫瘤細胞，從而消除下游研究中的潛在偽影。 因此，由於負濃縮方法優於其他濃縮技術，預計該細分市場將顯著增長。

因此，由於上述因素，市場細分預計將對市場增長做出重大貢獻。

北美將佔據很大的市場份額，預計在預測期內也會如此

由於癌症負擔增加、產品批准和研發活動增加等因素，預計北美將對顯著的市場增長做出貢獻。 例如，據2022年美國癌症協會估計，2022年全國將診斷出約236,740例肺癌新病例。 根據同一數據，2022 年將報告 79,000 例腎癌新病例和 13,920 例腎癌死亡病例。 癌症的高負擔預計將增加對 CTC 檢測試劑盒的需求，從而推動市場增長。

此外，預計所研究市場的產品批准將進一步推動市場增長。 例如，2020 年 11 月，美國食品和藥物管理局 (FDA) 擴大了一種被稱為液體活檢的血液檢測的批准用途，以幫助醫生為一些癌症患者選擇最佳治療方案。我做到了 該測試可識別釋放到血液中的腫瘤細胞 DNA 中與癌症相關的遺傳變化。

此外，根據 2020 年 2 月發表的“癌細胞改變蛋白質生產機制以加速轉移”的研究，從乳腺癌患者血液中富集的 CTCs 具有高水平的核醣體蛋白 (RP)，它們的存在具有與疾病侵襲性增加和臨床結果差有關。 因此，評估 CTC 中核醣體蛋白存在的研究將導致有效的癌症診斷，從而推動市場。 在美國還有 CellSearch 循環腫瘤細胞試劑盒，它是美國食品和藥物管理局 (FDA) 批准的最成功的產品之一。 該產品通過多個州的各種公共和私人支付機構提供報銷設施，包括 Cigna Government Services、Noridian 和 United Healthcare。 美國的幾所大學依靠 CTC 應用來推進病理學和實驗醫學的實踐。

因此，由於上述所有因素，預計該市場在預測期內將呈現高速增長。

競爭格局

由於大大小小的參與者的存在，市場得到了合理的整合。 一些市場參與者包括 Advanced Cell Diagnostics Inc.、Aviva Biosciences、Biocept Inc.、Creatv Micro Tech、LungLife AI Inc.、Menarini Silicon Biosystems、Miltenyi Biotec、Precision For Medicine（前身為 ApoCell）和 Qiagen NV。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 生物醫學成像和生物工程技術的進步
    • 對預防醫學和伴隨診斷的需求不斷增長
    • 癌症患病率增加
  • 市場製約因素
    • 與高診斷成本相關的 CTC 檢測和表徵技術困難
    • 缺乏認可，也不願意採用先進的 CTC 技術
  • 波特的五力分析
    • 新人進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按技術
    • CTC 富集方法
      • 積極充實
      • 負面充實
      • 其他技術
    • CTC檢測方法
      • 免疫細胞化學法
      • 分子（RNA）基礎技術
      • 其他 CTC 檢測方法
  • 通過申請
    • 多體性
    • RNA 分析
    • 蛋白質表達
    • 細胞間通訊
    • 其他應用
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Advanced Cell Diagnostics Inc.
    • Aviva Biosciences
    • Biocept Inc.
    • Creatv Micro Tech Inc.
    • LungLife AI Inc.
    • Menarini Silicon Biosystems
    • Miltenyi Biotec
    • Precision for Medicine（Formerly ApoCell）
    • Qiagen NV
    • BioChain Institute Inc.
    • Thermofisher
    • Sysmex Corporation

第七章市場機會與未來趨勢

簡介目錄
Product Code: 60459

The circulating tumor cells (CTC) market is expected to register a CAGR of 9.5% during the forecast period (2022-2027).

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled "Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study" in September 2020 reported that a total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Thus, this indicates that due to COVID-19, there were disruptions in cancer care regarding reduced chemotherapy and radiotherapy services and ongoing research and development studies, thereby impacting the market growth.

Additionally, the study "Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer," published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA and reported that tumor burden in patients who received a diagnosis after the lockdown was significantly higher compared with those who were diagnosed before the lockdown. This study indicated that the tumor burden increased during COVID-19 significantly and thus dramatically impacted the market growth.

The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology; the rising demand for preventive medicine and companion diagnostics; and the growing prevalence of cancer.

The global cancer burden is increasing; thus, cancer therapies must be modified according to regional and national priorities. For instance, according to the September 2021 update by the World Health Organization (WHO), cancer accounted for approximately 10 million worldwide deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).

In addition, as per the 2020 statistics by Globocan, 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people with cancer is estimated to reach 30.2 million by 2040. The increasing cancer burden is due to several factors, such as population growth and aging and the changing prevalence of specific causes of cancer linked to social and economic development. For instance, as per the World Health Organization (WHO), in September 2021, about one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity. Thus, increasing tobacco consumption is expected to cause an increase in the prevalence of cancer, thereby contributing to market growth.

Moreover, the positive results from the recent clinical studies in the market may also boost and lead to significant market growth in the future. For instance, a study titled "Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors" was initiated in February 2021 to evaluate the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

Thus, owing to the factors above, the studied market is expected to grow significantly during the study period. However, technical difficulties in the detection and characterization of CTCs associated with the high cost of diagnosis, lack of awareness, and unwillingness to adopt advanced CTC technologies are expected to hamper the market's growth further.

Key Market Trends

The Negative Enrichment Segment is Expected to Hold a Major Market Share in the Circulating Tumor Cells (CTC) Market

In the case of the positive enrichment method, it cannot isolate CTCs depending on heterogeneous properties. However, the negative enrichment method can isolate heterogeneous and intact CTCs by precisely eliminating blood cells. Thus, such an advantage of negative enrichment technology is expected to increase its adoption over the coming years.

Moreover, the rising prevalence of the various types of cancer is anticipated to bolster the segment's growth in the near future. According to the International Agency of Research on Cancer, 2020 Statistics, liver cancer was the sixth most common cancer and the third leading cause of cancer deaths worldwide, with an estimated 905,677 new cases and 830,180 deaths. East Asia had the highest incidence, with 491,687 cases. Moreover, the incidence rate was 46,599 in North America and 26,128 in western Europe. Overall, the incidence rate of liver cancer is approximately three times higher in males than in females.

Furthermore, according to an article published by the American Cancer Society in January 2022, kidney cancer is among the ten most common cancers in both men and women in United States. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46, and in women is about 1 in 80, which is significantly high. Cancer prevention is one of the most significant challenges with this growing burden. The analysis of circulating tumor cells is a substantial aspect of monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs and research into the mechanisms of disease progression.

In addition, negative enrichment has advantages over positive enrichment in isolating CTCs, owing to which the segment is expected to witness high growth over the forecast period. For instance, the study titled "Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device," published in October 2021, stated that the negative enrichment approach is advantageous because it leads to the unbiased detection of CTCs and also produces intact tumor cells free of attached immuno-agents, eliminating potential artifacts in downstream studies. Thus, the market segment is expected to grow significantly with the advantages of negative enrichment methods over other enrichment technologies.

Thus, the studied segment is expected to contribute significantly to the market's growth owing to the abovementioned factors.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to contribute to the significant growth of the market owing to factors such as the increasing burden of cancer, product approvals, and rising research and development activities. For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving market growth.

Additionally, product approvals in the studied market are further expected to drive market growth. For instance, in November 2020, the Food and Drug Administration (FDA) expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells released into the blood.

Moreover, according to a study, "Cancer cells alter protein production machinery to hasten metastasis," published in February 2020, CTCs enriched from the blood of breast cancer patients have higher levels of ribosomal proteins (RP), and their presence is associated with increased disease aggressiveness and poor clinical outcomes. Thus, studies evaluating the presence of ribosomal proteins in CTCs will lead to an effective cancer diagnosis, thus driving the market. In addition, United States has one of the most successful products, the CellSearch Circulating Tumor Cell Kit, which is approved by the US Food and Drug Administration (FDA). The product has reimbursement facilities through various public and private payers in several states, such as Cigna Government Services, Noridian, and United Healthcare. Several universities across United States have relied on CTCs applications to advance the practice of pathology and laboratory medicine.

Thus, the market studied is expected to witness high growth over the forecast period owing to all the factors above.

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, and Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology
    • 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics
    • 4.2.3 Increasing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis
    • 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Technology
    • 5.1.1 CTC Enrichment Methods
      • 5.1.1.1 Positive Enrichment
      • 5.1.1.2 Negative Enrichment
      • 5.1.1.3 Other Technologies
    • 5.1.2 CTC Detection Methods
      • 5.1.2.1 Immunocytochemical Technology
      • 5.1.2.2 Molecular (RNA)-based Technology
      • 5.1.2.3 Other CTC Detection Methods
  • 5.2 By Application
    • 5.2.1 Multiple Chromosome Abnormalities
    • 5.2.2 RNA Profiling
    • 5.2.3 Protein Expression
    • 5.2.4 Cellular Communication
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Advanced Cell Diagnostics Inc.
    • 6.1.2 Aviva Biosciences
    • 6.1.3 Biocept Inc.
    • 6.1.4 Creatv Micro Tech Inc.
    • 6.1.5 LungLife AI Inc.
    • 6.1.6 Menarini Silicon Biosystems
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Precision for Medicine (Formerly ApoCell)
    • 6.1.9 Qiagen NV
    • 6.1.10 BioChain Institute Inc.
    • 6.1.11 Thermofisher
    • 6.1.12 Sysmex Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS